Opportunity Information: Apply for RFA HL 15 008
Apply for RFA HL 15 008
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Bioreactors for Reparative Medicine (R43/R44)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health 93.350 National Center for Advancing Translational Sciences 93.837 Cardiovascular Diseases Research 93.838 Lung Diseases Research 93.839 Blood Diseases and Resources Research.
- This funding opportunity was created on Jul 24, 2014 and posted on Jul 24, 2014.
- Applicants must submit their applications by Oct 14, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $15,975,000.00 to eligible and selected applicants.
- The number of recipients for this funding is limited to 19 candidate(s).
- Eligible applicants include: Small businesses.
- Other Eligible Applicants include the following Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity. A small business concern is one that, at the time of award of Phase I and Phase II, meets all of the following criteria 1. Is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor 2. Is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture 3. (i) SBIR and STTR. Be a concern which is more than 50 percent directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50 percent directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these OR (ii) SBIR only. Be a concern which is more than 50 percent owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50 percent of the concern OR (iii) SBIR and STTR. Be a joint venture in which each entity to the joint venture must meet the requirements set forth in paragraph 3 (i) or 3 (ii) of this section. A joint venture that includes one or more concerns that meet the requirements of paragraph (ii) of this section must comply with 121.705(b) concerning registration and proposal requirements. 4. Has, including its affiliates, not more than 500 employees.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Bioreactors for Reparative Medicine (R43/R44) funding opportunity (RFA-HL-15-008) was an NIH small business grant program designed to push tissue engineering beyond basic, rudimentary culture approaches and toward advanced bioreactor systems that more realistically recreate how human tissues function. The core problem it targets is that many lab-grown tissues still fall short of being truly functional or reliable at scale because current growth technologies do not adequately mimic the real, dynamic conditions cells experience in the body. In response, NIH sought proposals that build sophisticated, biomimetic culture platforms capable of tightly controlling the cellular microenvironment and the three-dimensional (3D) organ-like context in which cells grow, with a particular focus on the unique physiological demands of heart, lung, and blood-related tissues.
A central theme of the announcement is precision control of the tissue environment. This includes the ability to regulate factors like nutrient and oxygen delivery, waste removal, mechanical forces, flow and shear stress, pressure changes, and other organ-specific dynamics that strongly influence maturation and function. Rather than simply growing cells in static dishes, the program emphasized complex systems that can better emulate in vivo-like conditions, because those conditions are often what drive cells to organize properly, differentiate appropriately, and exhibit the behaviors required for useful research models, preclinical testing, or eventual therapeutic applications.
The opportunity also makes clear that technical novelty alone is not enough; the bioreactor technology should be built in a way that supports real-world adoption in preclinical research workflows. Awarded projects were expected to show evidence that they are developing or using Good Laboratory Practice (GLP) standards and/or Good Manufacturing Practice (GMP) standards, since these quality frameworks are widely used to ensure consistency, traceability, and reliability. In practical terms, NIH was signaling that successful applicants should be thinking early about reproducibility, documentation, process controls, and quality systems that reduce the gap between a promising prototype and a platform that can be trusted by pharmaceutical, biotech, and translational research users.
Another key requirement is attention to biological variability, especially variability introduced by cell sources and cell handling. Applicants were expected to discuss sources of cell variability and address them in the context of measurement assurance and potential use of reference materials. This reflects a common pain point in tissue models: even well-designed systems can produce inconsistent outcomes if cell inputs vary by donor, lot, passage number, differentiation method, or handling history. By asking for discussion of measurement assurance and reference materials, the program aimed to promote approaches that improve comparability across runs, across sites, and over time, such as standardized benchmarks, calibration approaches, or well-characterized control materials that can reveal when results are drifting due to biological or process variability.
For projects that aimed to develop clinical-grade bioreactors and/or conduct clinical investigations, NIH required evidence of early engagement with the U.S. Food and Drug Administration (FDA). Applicants needed to show that they had contacted the FDA for guidance on development of the bioreactor device, including documentation such as correspondence related to an Investigational New Drug (IND) application (as relevant) and a timeline situating the work within federal regulatory approval processes. This requirement underscores that, if a bioreactor is intended for clinical manufacturing or to support clinical use, the regulatory pathway and FDA expectations must be addressed upfront rather than treated as an afterthought.
From an administrative and eligibility standpoint, this was a discretionary grant opportunity using the SBIR phased mechanism (R43/R44), meaning it supported both early feasibility work (Phase I) and follow-on development (Phase II) for qualifying small businesses. Only U.S. small business concerns were eligible, with standard SBIR requirements: the company must be for-profit, based in the United States (and operating primarily in the U.S. or contributing significantly to the U.S. economy), have no more than 500 employees including affiliates, and meet specific ownership/control rules (including allowable structures involving U.S. individuals, other qualifying U.S.-controlled businesses, and certain SBIR-only investment ownership configurations). The agency listed was NIH, and the activity category was health, with the scientific scope aligned to cardiovascular, lung, and blood disease areas as reflected in the related CFDA listings.
In terms of scale and timing, NIH anticipated making around 19 awards with an estimated total funding level of $15,975,000. The opportunity was posted July 24, 2014, and the original and final closing date was October 14, 2016, after which it was archived (archive date November 14, 2016). Overall, the announcement positioned bioreactor innovation as a practical enabling technology for reparative medicine, aiming to fund small businesses building next-generation systems that combine biological realism (organ-relevant dynamics in 3D culture) with quality, reproducibility, and a credible path toward preclinical and potentially clinical use.
Frequently Asked Questions (FAQs): Bioreactors for Reparative Medicine (R43/R44) (RFA-HL-15-008)
What is the Bioreactors for Reparative Medicine (R43/R44) opportunity?
This was an NIH Small Business Innovation Research (SBIR) funding opportunity (R43/R44) under the title "Bioreactors for Reparative Medicine" (RFA-HL-15-008). It was designed to move tissue engineering beyond basic culture methods and toward advanced bioreactor systems that better recreate how human tissues function under realistic, in-body-like conditions.
What problem was NIH trying to solve with this program?
The opportunity targeted a common limitation in tissue engineering: many lab-grown tissues are not fully functional or reliably reproducible at scale because standard growth approaches do not mimic the dynamic conditions cells experience in the human body. NIH sought bioreactor platforms that can recreate those dynamic conditions so engineered tissues mature and behave more like real tissues.
What kinds of technologies or platforms were encouraged?
NIH encouraged sophisticated, biomimetic culture platforms (bioreactors) that tightly control the cellular microenvironment and support three-dimensional (3D), organ-like tissue context. The emphasis was on systems that can emulate in vivo-like dynamics rather than static cell culture in dishes.
Which tissue or disease areas were specifically emphasized?
The announcement placed particular focus on the physiological demands of heart, lung, and blood-related tissues, aligning with NIH interests in cardiovascular, lung, and blood disease areas.
What does "precision control of the tissue environment" mean in this opportunity?
It refers to the ability of a bioreactor system to regulate key environmental factors that influence tissue maturation and function, including nutrient and oxygen delivery, waste removal, mechanical forces, flow and shear stress, pressure changes, and other organ-specific dynamics.
Why did the program emphasize dynamic, in vivo-like conditions instead of static culture?
The program emphasized dynamic conditions because those conditions often drive cells to organize properly, differentiate appropriately, and exhibit behaviors needed for practical use. Static culture approaches frequently fail to produce tissues that are realistic enough for dependable research models, preclinical testing, or downstream therapeutic pathways.
Was technical novelty by itself considered sufficient?
No. The opportunity explicitly emphasized that novelty alone was not enough. Proposed bioreactor technology was expected to support real-world adoption in preclinical research workflows, with attention to reproducibility and quality systems.
What quality or compliance expectations were highlighted (GLP/GMP)?
Awarded projects were expected to show evidence that they were developing or using Good Laboratory Practice (GLP) standards and/or Good Manufacturing Practice (GMP) standards. NIH signaled that applicants should plan for reproducibility, documentation, process controls, and quality systems early to reduce the gap between prototype systems and platforms that can be trusted in translational settings.
How did the opportunity address reproducibility and reliability?
Beyond GLP/GMP considerations, the opportunity emphasized controlling and documenting factors that influence outcomes and implementing process controls that support consistent performance over time. It also specifically called out biological variability as a major reproducibility challenge that applicants needed to address.
What does the program mean by "biological variability," and why was it important?
Biological variability refers to differences introduced by cell sources and handling, such as donor-to-donor differences, lot differences, passage number, differentiation methods, and handling history. NIH emphasized this because even strong engineering can produce inconsistent results if cell inputs vary in uncontrolled ways.
What were applicants expected to discuss regarding cell variability?
Applicants were expected to discuss sources of cell variability and explain how they would address variability through measurement assurance and potential use of reference materials.
What are "measurement assurance" and "reference materials" in this context?
Within the scope described, measurement assurance and reference materials relate to approaches that improve comparability across runs, sites, and time. Examples mentioned conceptually include standardized benchmarks, calibration approaches, or well-characterized control materials that help detect drift or variation caused by biological inputs or process changes.
Were there special requirements for projects aiming at clinical-grade bioreactors or clinical investigations?
Yes. For projects proposing clinical-grade bioreactors and/or clinical investigations, NIH required evidence of early engagement with the U.S. Food and Drug Administration (FDA).
What FDA-related documentation was required (as described in the opportunity summary)?
Applicants needed to show that they had contacted the FDA for guidance on development of the bioreactor device, including documentation such as FDA correspondence related to an Investigational New Drug (IND) application (as relevant) and a timeline placing the work within federal regulatory approval processes.
What was the funding mechanism used by this opportunity?
This was a discretionary NIH grant opportunity using the SBIR phased mechanism (R43/R44), supporting both Phase I (early feasibility) and Phase II (follow-on development) for qualifying small businesses.
Who was eligible to apply?
Only U.S. small business concerns were eligible, under standard SBIR requirements.
What are the key SBIR small business eligibility requirements mentioned?
The company had to be for-profit, based in the United States (and operating primarily in the U.S. or contributing significantly to the U.S. economy), have no more than 500 employees including affiliates, and meet specific SBIR ownership/control rules. Allowable ownership/control structures included U.S. individuals, other qualifying U.S.-controlled businesses, and certain SBIR-only investment ownership configurations.
Which federal agency administered this opportunity?
The agency listed was the National Institutes of Health (NIH).
What activity category and general scientific domain did it fall under?
The activity category was health, with scope aligned to cardiovascular, lung, and blood disease areas (as reflected in the related CFDA listings described).
How many awards and how much total funding were anticipated?
NIH anticipated making around 19 awards, with an estimated total funding level of $15,975,000.
When was the opportunity posted and when did it close?
The opportunity was posted on July 24, 2014. The original and final closing date was October 14, 2016.
Is this opportunity still open?
No. It was archived after the final closing date, with an archive date of November 14, 2016.
What was the overall goal or positioning of the announcement?
The announcement positioned bioreactor innovation as enabling technology for reparative medicine by funding small businesses to build next-generation systems that combine biological realism (organ-relevant dynamics in 3D culture) with quality, reproducibility, and a credible path toward preclinical and potentially clinical use.
Browse more opportunities from the same category: Health
Next opportunity: BLM AK CESU AKNHP Botanical and Invasive Species Support
Previous opportunity: BLM AK F 82 Archaeology and Education
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 15 008
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 15 008) also looked into and applied for these:
| Funding Opportunity |
|---|
| Paul B. Beeson Clinical Scientist Development Award in Aging (K08) Apply for RFA AG 15 016 Funding Number: RFA AG 15 016 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Paul B. Beeson Patient Oriented Research Career Development Award in Aging (K23) Apply for RFA AG 15 017 Funding Number: RFA AG 15 017 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS CREATE Devices Translational and Clinical Studies on the Path to 510(k) (UH2/UH3) Apply for PAR 14 295 Funding Number: PAR 14 295 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS CREATE Devices Translational and Clinical Studies on the Path to 510(k) (U44) Apply for PAR 14 296 Funding Number: PAR 14 296 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS CREATE Devices Translational and Clinical Studies to Inform Final Device Design (UH2/UH3) Apply for PAR 14 297 Funding Number: PAR 14 297 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS CREATE Devices Translational and Early Feasibility Studies on the Path to Pre Market Approval (PMA) or Humanitarian Device Exemption (HDE) (UH2/UH3) Apply for PAR 14 298 Funding Number: PAR 14 298 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS CREATE Devices Translational and Early Feasibility Studies on the Path to Pre Market Approval (PMA) or Humanitarian Device Exemption (HDE) (U44) Apply for PAR 14 299 Funding Number: PAR 14 299 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS CREATE Devices Translational and Clinical Studies to Inform Final Device Design (U44) Apply for PAR 14 300 Funding Number: PAR 14 300 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Detect, Define and Measure the Progression of Chronic Traumatic Encephalopathy (U01) Apply for RFA NS 14 012 Funding Number: RFA NS 14 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Enhance global health security and implementation of International Health Regulations. Apply for EP IDS 14 014 Funding Number: EP IDS 14 014 Agency: Assistant Secretary for Preparedness and Response Category: Health Funding Amount: $350,000 |
| Office of Tribal Self Governance Program Planning Cooperative Agreement Apply for HHS 2014 IHS TSGP 0001 Funding Number: HHS 2014 IHS TSGP 0001 Agency: Indian Health Service Category: Health Funding Amount: $120,000 |
| Tuskegee University Apology Commemoration Activities Apply for CDC RFA PS15 1504 Funding Number: CDC RFA PS15 1504 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $300,000 |
| Enhancing Cross National Research within the Health and Retirement Study Family of Studies (R01) Apply for RFA AG 15 015 Funding Number: RFA AG 15 015 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NHLBI Career Transition Award for Intramural Fellows (K22) Apply for PAR 14 302 Funding Number: PAR 14 302 Agency: National Institutes of Health Category: Health Funding Amount: $249,000 |
| The NIGMS Human Genetic Cell Repository (U42) Apply for RFA GM 15 005 Funding Number: RFA GM 15 005 Agency: National Institutes of Health Category: Health Funding Amount: $2,800,000 |
| Institutional Development Award (IDeA) Program Infrastructure for Clinical and Translational Research (IDeA CTR)(U54) Apply for PAR 14 303 Funding Number: PAR 14 303 Agency: National Institutes of Health Category: Health Funding Amount: $4,000,000 |
| USAID/Uganda Karamoja Health Apply for RFA 617 14 000010 Funding Number: RFA 617 14 000010 Agency: Uganda USAID Kampala Category: Health Funding Amount: $20,000,000 |
| Immune and Inflammatory Mechanisms in Alzheimers Disease (R01) Apply for RFA AG 15 018 Funding Number: RFA AG 15 018 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| USAID/Uganda Social Marketing Activity Apply for RFA 617 14 000011 Funding Number: RFA 617 14 000011 Agency: Uganda USAID Kampala Category: Health Funding Amount: $24,000,000 |
| NIMH Mentoring Networks for Mental Health Research Education (R25) Apply for PAR 14 304 Funding Number: PAR 14 304 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 15 008", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.